49 results on '"Mansutti, A"'
Search Results
2. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial
3. Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies
4. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial
5. Computational corroboration of the flow of rock glaciers against borehole measurements
6. Feasibility study of a novel class of plasma antennas for SatCom navigation systems
7. Nursing students' involvement in shift-to-shift handovers: Findings from a national study
8. Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey
9. When are night shifts effective for nursing student clinical learning? Findings from a mixed-method study design
10. Instruments evaluating the quality of the clinical learning environment in nursing education: A systematic review of psychometric properties
11. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis
12. C18 - Strategy of monitoring metastatic breast cancer (M-MBC) in clinical practice: more or less intensive?
13. 209P Trastuzumab plus lapatinib or chemotherapy in patients with HER2-positive advanced breast cancer refractory to anti-HER2 therapies: A randomized, multicenter, phase II trial (GIM12-TYPHER)
14. 101P Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: An individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies
15. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
16. C30 - Neutrophil-to-lymphocyte ratio in metastatic breast cancer patients: relationship with tumor characteristics and survival
17. C29 - Small luminal-like breast cancer: determinants of adjuvant chemotherapy use
18. C19 - Monitoring metastatic breast cancer (M-MBC) during treatment: a GIM (Gruppo Italiano Mammella) survey
19. C10 - Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer
20. A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer
21. Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study
22. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer
23. 249P A retrospective analysis on capecitabine and vinorelbine combination in metastatic breast cancer: The MARCELLINO study
24. 134O Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)
25. A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer
26. Taxane-induced nail changes: incidence, clinical presentationand outcome
27. A Lorenz-like model for the horizontal convection flow
28. Multimodal treatment with primary single-agent epirubicin in operable breast cancer: 5-year experience of the Michelangelo Cooperative Group
29. Numerical modelling of liquid/solid phase transitions: Analysis of a gallium melting test
30. 295P Clinical characterization and outcome of a HER2-low metastatic breast cancer (mBC) cohort receiving first-line treatment (1L) with ET +/- CDK 4/6 inhibitor (CDKi)
31. 252P Does the introduction of CDK4/6 inhibitors (CDKi) in first-line treatment of metastatic breast cancer (MBC) increase medical oncology workload?
32. 141P Gene-expression pathways and dynamics during neoadjuvant chemo-free therapy predict pathologic complete response in ER+/HER2+ breast cancer (BC)
33. 118O Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella
34. Coincidence of the linear and non-linear stability bounds in a horizontal thermal convection problem
35. 342P Different modalities of detection breast cancer recurrences: A 5-year retrospective cohort study
36. 335P - Safety and efficacy of ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study
37. 271P - Association of derived neutrophil-to-lymphocyte ratio (dNLR) with pathological complete response (pCR) after neoadjuvant chemotherapy (CT)
38. 236P - Clinical decision making and multidisciplinary team meetings (MDMs) in early breast cancer. Is the agreement between planned and applied therapeutic program?
39. 302P - A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients
40. T6 - Final results from CAMEO-PRO study: complementary and alternative medicine in oncology. physicians inform oncological patients
41. 287P - Neutrophil-to-lymphocyte ratio in metastatic breast cancer: Association with clinico-pathological features and outcome
42. 199P - Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios in breast cancer
43. F14 - Last-line treatment of luminal metastatic breast cancer: which factors influence the therapeutic choice?
44. F15 - Treatment strategies in patients with Metastatic Breast Cancer: real-world practice in the United Kingdom (UK) and Italy
45. A37 - Lung cancer patients and unplanned presentations to hospital: insights from a single institution experience
46. Flow of a shear thinning fluid between intersecting planes
47. Jefferey-Hamel flow of power-law fluids for exponent values close to the critical value
48. Non-similar flow of a non-newtonian fluid past a wedge
49. Tamoxifene (TAM) and primary breast cancer in old women
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.